BACKGROUND: General practitioners (GPs) play a pivotal role in the long-term management of @entity1 with @entity955 ( @entity955 ), including anticoagulant prophylaxis for @entity64 prevention. AIMS: To investigate the antithrombotic prescription behaviours of GPs in France and compare them with the European Society of Cardiology (ESC) guidelines for @entity64 prevention, and to identify the major determinants of use of antithrombotic therapy. METHODS: We conducted a cross-sectional survey, using data from the French Longitudinal @entity1 Database, on the use of antithrombotic treatments for @entity64 prevention in 15,623 @entity1 (>= 18years of age) with @entity955 who attended at least one GP consultation between July 2010 and June 2011. Data were collected on @entity1 baseline characteristics, @entity64 risk factors, and prescription of antithrombotic drugs. RESULTS: The mean age was 74.6  11.1years, 59.5% were @entity1 , and 83.1% had a CHADS2 score>= 1. Over half (52.6%) of the @entity1 with a CHADS2 score>= 1 received a @entity2067 antagonist (alone or in combination with an antiplatelet), 19.3% received @entity117 alone, and 23.4% received no antithrombotic therapy; 3.6% of the @entity1 received dual antiplatelet therapy and 1.1% @entity1397 alone. Over half of the @entity1 (56.3%) were treated in accordance with the ESC 2010 guidelines. Of the remaining @entity1 , 19.4% received no treatment, 13.0% were inadequately treated, and 11.2% were over-treated. Factors associated with antithrombotic treatment were anti-arrhythmic therapy, higher @entity64 risk, presence of @entity66 , and use of non-steroidal anti-inflammatory drugs. Female gender was associated with a lower likelihood of antithrombotic treatment. CONCLUSIONS: In this large French study, approximately 45% of @entity1031 high-risk @entity1 were either not treated or inadequately treated. Better compliance with evidence-based guidelines is needed to reduce the burden of @entity64 in the @entity955 population.

Discrepancy between guidelines for @entity64 prevention in XXXX and practice patterns in primary care. The nationwide French AFIGP survey.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient', 'men'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity66 :: ('MESH:D004194', 'Disease') :: ['atherothrombotic disease'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF']
@entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']
